Johnson & Johnson’s immunoselective monoclonal antibody Imaavy (nipocalimab) has been approved by the European Commission to treat individuals with generalised myasthenia gravis (gMG) 12 years old and over.
Johnson & Johnson’s immunoselective monoclonal antibody Imaavy (nipocalimab) has been approved by the European Commission to treat individuals with generalised myasthenia gravis (gMG) 12 years old and over.